Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR4 | P51679 | 16/20 | 0.71 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.64 |
| ▸ | EDNRA | P25101 | 3/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30743778 | 1.00 | CCR4 (0.71) | CCR4ABCB11EDNRA | |
| SCHEMBL27425770 | 0.87 | CCR4 (0.69) | CCR4ABCB11EDNRA | |
| SCHEMBL25083900 | 0.86 | CCR4 (0.65) | CCR4ABCB11EDNRA | |
| SCHEMBL30844537 | 0.86 | CCR4 (0.65) | CCR4ABCB11EDNRA | |
| SCHEMBL1731223 | 0.85 | CCR4 (0.82) | CCR4ABCB11EDNRA | |
| SCHEMBL8038435 | 0.85 | ABCB11 (0.74) | CCR4ABCB11EDNRA | |
| SCHEMBL1731814 | 0.83 | CCR4 (1.00) | CCR4EDNRA | |
| SCHEMBL1732589 | 0.83 | CCR4 (0.83) | CCR4EDNRA | |
| SCHEMBL30296218 | 0.83 | ABCB11 (0.75) | CCR4ABCB11EDNRA | |
| SCHEMBL7359279 | 0.83 | ABCB11 (0.75) | CCR4ABCB11EDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287053-A1 | COMPOUND, ENDOTHELIN-A RECEPTOR ANTAGONIST, AND PHARMACEUTICAL COMPOSITION | ALCHEMEDICINE, INC. (JP) | 2024-08-29 | — | — | US | disclosed |
| CN-117255791-A | Compounds, endothelin A receptor antagonists and pharmaceutical compositions | 亚克医药株式会社 | 2023-12-19 | — | — | CN | disclosed |
| WO-2022270487-A1 | COMPOUND, ENDOTHELIN-A RECEPTOR ANTAGONIST, AND PHARMACEUTICAL COMPOSITION | 株式会社アークメディスン | 2022-12-29 | — | — | WO | disclosed |
| WO-2022270487-A1 | COMPOUND, ENDOTHELIN-A RECEPTOR ANTAGONIST, AND PHARMACEUTICAL COMPOSITION | 株式会社アークメディスン | 2022-12-29 | — | — | WO | disclosed |
| US-6060475-A | Substituted pyrazin-2-yl-sulphonamide-(3-pyridyl) compounds and uses thereof | ZENECA LIMITED (GB) | 2000-05-09 | — | — | US | disclosed |
| US-5866568-A | ENDOTHELIN RECEPTOR ANTAGONIST ACTIVITY | ZENECA LIMITED (GB) | 1999-02-02 | — | — | US | disclosed |
| EP-0832082-A1 | N-HETEROARYL-PYRIDINESULFONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ZENECA LIMITED (GB) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996040681-A1 | N-HETEROARYL-PYRIDINESULFONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ZENECA LIMITED (GB) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287053-A1 | COMPOUND, ENDOTHELIN-A RECEPTOR ANTAGONIST, AND PHARMACEUTICAL COMPOSITION | EDNRA, EDNRB, ECE1 | CCR4 1408/4885ABCB11 682/4885EDNRA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.